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Stephen L Michell1 and Ray Sheridan6Abstract
Background: Clostridium difficile infection poses a significant healthcare burden. However, the derivation of a
simple, evidence based prediction rule to assist patient management has not yet been described.
This study aimed to identify such a prediction rule to stratify hospital inpatients according to risk of all-cause
mortality, at initial diagnosis of infection.
Method: Univariate, multivariate and decision tree procedures were used to deduce a prediction rule from over 186
variables; retrospectively collated from clinical data for 213 patients. The resulting prediction rule was validated on
independent data from a cohort of 158 patients described by Bhangu et al. (Colorectal Disease, 12(3):241-246, 2010).
Results: Serum albumin levels (g/L) (P = 0.001), respiratory rate (resps /min) (P = 0.002), C-reactive protein (mg/L)
(P = 0.034) and white cell count (mcL) (P = 0.049) were predictors of all-cause mortality. Threshold levels of serum
albumin≤ 24.5 g/L, C- reactive protein >228 mg/L, respiratory rate >17 resps/min and white cell count >12 × 103 mcL
were associated with an increased risk of all-cause mortality. A simple four variable prediction rule was devised based
on these threshold levels and when tested on the initial data, yield an area under the curve score of 0.754
(P < 0.001) using receiver operating characteristics. The prediction rule was then evaluated using independent data,
and yield an area under the curve score of 0.653 (P = 0.001).
Conclusions: Four easily measurable clinical variables can be used to assess the risk of mortality of patients with
Clostridium difficile infection and remains robust with respect to independent data.
Keywords: All-cause mortality, Clostridium difficile related mortality, Non-Clostridium difficile related mortality,
Clinical prediction ruleBackground
Clostridium difficile (C. difficile) is an anaerobic, spore
forming, rod shaped bacterium, and is a prevalent
Healthcare Care Associated Infection (HCAI). Furthermore,
antibiotic resistant strains of C. difficile are a growing
problem in the healthcare system [1]. Recent C. difficile
epidemics have been caused by hypervirulent strains
which became resistant to the fluoroquinolones soon
after their introduction into the healthcare setting [2].
Current UK approved therapy for C. difficile infection is* Correspondence: E.C.Keedwell@exeter.ac.uk
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reproduction in any medium, provided the ororal vancomycin, oral or intravenous metronidazole, or
fidaxomicin among other treatment regimens [3].
According to the National Office of Statistics, C. difficile
related deaths accounted for 1.1% of all deaths in England
and Wales between 2006 and 2010 with patients over
65 years having a particularly high incidence of mortality
[4]. Further difficulties are faced when trying to predict
recurrence, which occurs in approximately 20% of patients
following withdrawal of antibiotics and this makes
subsequent therapeutic choice more complex [5]. As well
as identifying significant risk factors for development of C.
difficile infection (CDI) it is also of clinical importance to
produce a valid system to describe severity and predict. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ment regimes.
Clinical prediction rules
There have been few studies which have generated simple
prediction rules for risk of mortality for patients with
HCAIs, and more specifically CDI. As discussed in a
recent BMJ article by Adams et al. (2012) [6] clinical
prediction rules that are simple to use in the busy hospital
setting and that add prognostic value to clinical evaluation
should be considered in more areas, as is highlighted by
the successful implementation of scoring systems such
as CURB-65 in patients with community acquired
pneumonia [7]. The implementation of a disease specific
score such as the CURB-65 clinical prediction rule has
helped predict mortality risk and guide treatment options
in patients with community acquired pneumonia. The
merits of CURB-65 clinical prediction rule are that it
relies upon only a few variables, and is now a clinically
wide-spread tool easily used non-specialists [7]. Thus, the
aim of this study was to develop a similar simple clinical
prediction rule that would help in a similar manner in
patients with CDI, and could easily be applied by non-
specialist or a junior doctor pending review by a more
experienced clinician. The identification of those patients
with CDI who are more at risk from mortality could
facilitate more targeted and intensive treatment regimens
[8] and facilitate bedside clinical decision making [9].
In 2012 a systematic review of prediction rules for
outcomes in CDI patients found only a small number of
studies (N = 13) which had derived rules for outcomes
such as severity of disease (N = 5), mortality, (N = 5),
recurrence, (N = 2) and response to therapy (N = 1) of
which, only two rules had been tested on a validation
cohort [10]. A recent publication by Bhangu et al. (2010)
[11] evaluated the use of significant clinical variables
identified by univariate and multivariate tests, for the
development of a scoring system to identify patients
with CDI who may be more at risk from death during
the course of infection. This study identified six clinical
variables and associated the following threshold values
in a cohort of 158 patients; age ≥ 80, clinical disease
severity, white cell count ≥ 20 × 103 mcL or C-Reactive
protein ≥ 150 mg/L, urea ≥ 15 mmol/L and serum albu-
min ≤ 20 g/L which could be used in combination to
score the relative risk of death in patients with CDI. By
assigning one point to each variable and using a score
from 0–5 (evaluated within the first 72 hrs of a toxin
positive stool sample) the risk of death increased as the
score increased. However, some of the variables used in
the scoring system are themselves derived from other
observations, making the system more complex and
more heavily reliant on clinician interpretation. Many of
the other rules [12-14] mentioned in the meta analysis[10] may also be underutilised in clinical practice due to
being over complicated with too many variables. Simple,
accurate prediction rules, relying on few variables, for
identifying the risk of mortality in patients with CDI;
that can be applied to a case within a clinical setting and
be used effectively to monitor patients’ treatment regimes,
are of great interest to healthcare system. Yet, as described
above there is little published literature regarding the
derivation and validation of clinical prediction rules for
CDI patients, further emphasising the necessity of being
able to readily identify patients who are more at risk from
death, in a simple, clear and accurate manner.
Study objective
This retrospective cohort study using an independent
validation cohort has been designed to obtain a simple
prediction rule to stratify hospital inpatients at initial
diagnosis of CDI according to risk of mortality, using
univariate, multivariate and decision tree procedures.
Method
Royal Devon and Exeter Hospital (RD&E) NHS Trust is
a 49 ward, 797 inpatient-bed hospital. The mean CDI
rate was 6.55 hospital apportioned cases per 10,000
bed days from the period March 2007- April 2009 as
reported by the Health Protection Agency. The national
average across England for the same period was 7.4
hospital apportioned cases per 10,000 bed days. The
range of incidences of trust apportioned cases of CDI
per 10000 bed days derived from 165 hospitals in England
was 0.1-14.6 during the same period.
Inclusion criteria for this study were symptomatic
patients with a C. difficile toxin A/B positive stool sample
using the TechLab® C.diff Quik Chek Complete™ Enzyme
linked Immuno-assay (Alere Ltd, UK), who were transferred
to the specialised C. difficile cohort ward between 2007
and 2009. This cohort ward is a 19 bed ward with 7
double doored, single occupancy side rooms and cohorted
bays with closed doors. Patients were managed by a
multi-disciplinary specialist team including a physician,
microbiologist, antibiotic pharmacist, infection control
nurse and physiotherapists. Having identified the study
population, the clinical notes were reviewed for the admis-
sion period during which the positive toxin result was
confirmed. Information parameters collected and used
in analysis included: biographical details, concurrent medi-
cation (chemotherapy agents, gastro-suppressants and
steroids) co-morbidities, pre-admission place of residence,
pre-admission circumstance, antibiotic administration in
the previous two months, faecal calprotectin results, CDI
treatment regimes, routine blood tests and observations
at time of diagnosis. Clinical blood measurements and
routine observations i.e. blood pressure, respiratory rate
etc. were those first taken within 48 hours of a C. difficile
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ity in this study is; patients who had died from CDI and
non-CDI related causes as an inpatient, or had been
discharged and have then died ≤ 30 days. All patients were
followed for a minimum of 30 days post discharge and the
total number of patients in this study was 213. The total
number of cases for this study was 245, which included
29/213 patients with multiple C. difficile infections
(CDIs). This project did not require ethics approval
and it was clarified during scientific review that this is a
retrospective study and data would be anonymised and
collected as part of routine care.
Statistical analysis
While the outcome of interest was all-cause mortality,
statistical analysis was also used to deduce if there were
means and medians of variables that were more signifi-
cantly associated with either CDI or non-CDI related
mortality versus those who survived (comparator group).
Univariate and multivariate discovery of variables signifi-
cantly associated with CDI and non-CDI related mortality
was conducted on one set of patient (N = 213) data. For
mortality this included one set of data from those with
recurrent CDI, based on the last case entry, to account
for those which may have had a worse outcome on
subsequent infections. The data was anonymised and
input into PASW Statistics 18 (SPSS Inc, IBM, USA).
Nominal variables were converted into binary format
unless dates were used as an input value.
All variables (Additional file 1) were then tested for
normality for the outcome measure all-cause mortality
using the Shapiro-Wilk test, where a P > 0.05 value was
associated with normally distributed data.
All the demographic and baseline clinical characteristic
data outlined above and in the supplementary data
(Additional file 1), was used in univariate and multivariate
analysis to identify variables significantly associated with
mortality. All variables were tested for significance in
relation to the outcome measures by independent median
tests, One-Way ANOVA and Chi-squared (χ2) tests.
Variables which remained statistically significant after
Bonferroni correction (where P = 0.05/N; N = number of
variables being tested on a test by test basis) were used in
the regression model.
Variables independently associated with CDI related
mortality and non-CDI related mortality versus the
comparator group, were subject to multinomial logistic
analysis on a patient basis. All significant variables were
entered using a block entry method. Any missing data
was excluded on a test by test basis and some data was
not included in the analysis, to leave a portion of the
data as ‘unseen’ to avoid overfitting in the classification
and regression tree (CRT) analysis. These algorithms,
whilst powerful, can overfit their training data and developmodels that are overspecialised to one dataset. The use
of a separate testing set to reduce this effect is standard
practice in classification research.
Model derivation
For the purpose of prediction rule derivation in this
study, the mortality outcome was grouped into two
categories (died and survived). The prediction rule was
derived by inputting all 245 cases of data (patients with
primary only and recurrent CDI) into the analysis, which
was then split into training and test data (50:50) in order
that a sufficient amount of data was captured in each
portion. A decision tree classification model was used to
predict values of a dependent (target) variable based on
values of independent (predictor) variables (SPSS Inc).
All results for derivation of threshold values are reported
on test data. (Model criteria can be found in the
Additional file 1).
Variables and their respective threshold values which
were found during multivariate analysis and test data of
classification analysis were assigned a score to create a
prediction rule which was then applied to the derivation
and validation cohort for all applicable cases.
Model validation
Independent data from 158 patients with CDI obtained
from a UK teaching hospital, as described by the Bhangu
et al. (2010) study [11] was used to validate the prediction
rule generated in the derivation cohort. The prediction
rule, excluding the variable respiratory rate (due to lack
of data for this measure) was evaluated in each cohort
by receiver operating characteristic (ROC) curves.
Results
Derivation cohort demographics
54% (115) of the population were female. 71% (174) of
cases were admitted for acute medical care, 10% (25) of
cases were admitted due to community acquired CDI and
the remaining cases were admitted for; elective surgery
(7), emergency surgery (15), trauma (12), planned proce-
dures (1) or renal care (11). 78% (191) cases were origin-
ally admitted from the home environment, 13.5% (33) of
cases were originally admitted from another hospital
and 8.6% (21) of cases were originally admitted from
long term care facilities. All but three cases (who were
later transferred to the intensive care ward) were admitted
and treated in the Clostridium difficile cohort ward.
Mortality
For this study cohort, 76% (162) of patients survived to
discharge with the remaining 24% (51) either surviving
to discharge then dying within 30 days (40), or dying
within 30 days of admission (11) (all-cause mortality).
The overall mortality rate for this cohort was 24% and
Table 1 Summary of the prediction rule
Variables
• 1 point for a Serum Albumin level ≤ 24.5 (g/L)
• 1 point for a CRP level > 228 (mg/L)
• 1 point for a combination of WCC > 12 (mcL) and respiratory rate >
17 (resps/min)
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died at any stage after admission 53% (27) of these death
certificates had C. difficile in part one or two according
to the department of health guidelines [15] (CDI related
mortality). Of these 27 deaths, 9 (33%) were due to CDI
(listed in part one of the death certificate, according to
the department of health report [15]) and 18 (66%) were
not directly due to CDI but it was mentioned on the
death certificate (listed in part two of the death certificate,
according to the department of health report [15]). The
remaining 24 deaths were not attributed in any way to
CDI (non-CDI related mortality).
Severity of infection
Severity of infection was noted for all cases (using local
Department of Health guidelines [15]. There were 31.4%
(77) cases of mild infection, 13.9% (34) cases of moderate
infection, 47.3% (116) cases of severe infection and 7.3%
(18) cases of life threatening infection. 29 patients had >1
CDI which gives a 14% recurrence rate. Further patient
demographics can be seen in Additional file 1.
Prediction rule derivation
Univariate and multivariate analysis
Results of Bonferroni post hoc analysis after One-Way
ANOVA analysis revealed that there were significant
differences in serum albumin means (see Additional
file 1, for mean and median level pair wise compari-
sons) between the survival group and the groups; CDI
related mortality (P = < 0.001) and non-CDI related
mortality (P = 0.011), whilst Independent Samples K-
median tests determined that the difference in median
respiratory rate across the groups was significantly dif-
ferent (χ2(df = 2) =11.8; P = 0.003) from the grand median
(16 resps/min). The difference in median C-Reactive
protein (CRP) levels across the groups was determined to
be significantly different (χ2(df = 2) =14.2; P = 0.001) from
the grand median (89.50 mg/L), and the difference in
median white cell counts (WCC) across the groups was
determined to be significantly different (χ2(df = 2) =11.4;
P = 0.003) from the grand median (12 × 103 mcL).
Variables independently associated with the outcome
all-cause mortality (survival group [N = 124], versus the
group; CDI related mortality [N = 19], and non-CDI
related mortality [N = 18]) were subject to multinomial
logistic analysis on a patient basis. All significant variables
were entered using a block entry method. Results revealed
that the variables serum albumin level (P = 0.001), re-
spiratory rate (P = 0.002), CRP (P = 0.034) and WCC
(P = 0.049) significantly contributed to the model. Further
breakdown of the model (Additional file 1) revealed that
the variables respiratory rate and serum albumin were
significant predictors for both non-CDI related mortality
(P = 0.007; OR 1.186 and P = 0.004; OR 0.844) and CDIrelated mortality (P = 0.003; OR 1.222 and P = 0.001;
OR 0.801), whilst CRP (P = 0.020; OR 1.009) and WCC
(P = 0.025; OR 1.046) remained specifically statistically
significant for the group CDI related mortality. The
model showed an overall classification of 80.7%.
Decision tree classification results
Due to the small number of patients in both the CDI-
related mortality group and the non-CDI related mortality
groups, for the purpose of decision tree classification
analysis, these groups were merged into the single category
outcome; died. All the variables showing significant
association to both CDI-related and non-CDI related
mortality were entered in a decision tree model to look
for the measurements at which the tree partitioned the
data into the outcome groups died and survived. The
model used all four variables to classify test data (N =
120) and the overall accuracy of the model at classifying
the data was 75%. The model accurately predicted 47%
of cases into the outcome; died, and 80% of the survival
outcome cases correctly using these four variables
(Additional file 1). Inaccuracy in the test data may be due
to the fact that there were only a small percentage of cases
for the outcome, died.
Decision tree rules (not shown here) revealed that
low serum albumin (≤ 24.5 g/L) and/or high CRP levels
(> 228 mg/L) were both indicated in the increased
probability of death as an outcome, however, in patients
with serum albumin levels > 24.5 g/L and CRP levels >
228 mg/L, increased WCC (>12 × 103 mcL) and increased
respiratory rate (>17 resps/min) were all indicated in the
increased probability of death as an outcome.
Prediction rule
Based on the threshold levels indicated by the classifica-
tion model, a prediction rule was then developed (Table 1)
which assigned 1 point for a serum albumin level ≤ 24.5
g/L, 1 point for a CRP level > 228 mg/L and 1 point for a
combination of WCC >12 × 103 mcL and respiratory
rate > 17 resps/min as this proved more discriminatory
than either value alone. The summation of any combin-
ation of these variables as seen in Table 1, resulted in a
score from 0–3 which could classify the cases into the
group survived or died, in the all-cause mortality outcome.
This prediction rule was applied to all the cases and cross
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can be seen in Table 2 and Table 3 and showed that an
increasing score (0, 1, 2, 3) increases the risk of mortality
in patients with CDI.
As can be seen from Table 3, there is a linear increase
in mortality risk in relation to the score progression
from 0 to 3 points. A key point of the system is that the
mortality risk for 0-scored patients is approximately half
of the mean risk in the cohort as a whole.
Prediction rule validation
The prediction rule shown in Table 1 was validated on in-
dependent data from 158 patients with CDI obtained from
a UK teaching hospital as described by Bhangu et al. (2010)
[11]. Respiratory rate data was not available for this cohort
and so the prediction rule as derived in this study was run
again omitting respiratory rate as a predictor, thus 1 full
point was allocated to WCC >12 × 103 mcL. The simplified
prediction rule was tested on both data sets, and compared
to the rule derived in the Bhangu et al. [11] study, and re-
sults can be seen in Table 4.
ROC curves were used to evaluate the original predic-
tion rule and the prediction rule (excluding respiratory
rate) on both the derivation and validation cohort. The
original prediction rule yield an area under the curve
(AUC) in the derivation cohort of 0.754 (P < 0.001; 95%
CI: 0.670-0.837, data not shown) and the simplified
prediction rule (excluding respiratory rate) tested in the
derivation cohort (Figure 1) resulted in an AUC of 0.704
(P < 0.001; 95% CI: 0.619-0.790). The AUC of the simpli-
fied prediction rule was reduced by a further 5% to
0.653 (P = 0.001 95% CI: 0.565-0.741), when tested in
the validation cohort (Figure 2) but remained statisti-
cally significant thus demonstrating the robustness of
the prediction rule to new data.
Discussion
The prediction rule
This large retrospective cohort study has identified four
easily measurable clinical variables: serum albumin
level ≤ 24.5 g/L, CRP level >228 mg/L and a combinationTable 2 Cross tabulation of score for risk of mortality against
0
Died Count 16
(%) within Score for Mortality 9.5
Survived Count 153
(%) within Score for Mortality 90.5
Total Count 169
(%) within Score for Mortality 100.0
*One missing case due to lack of data for all variables.of WCC >12 × 103 mcL and respiratory rate >17 resps/min
(as this proved more discriminatory than either value alone)
that if measured within or around 48 hours of CDI diag-
nosis, are capable of predicting the risk of mortality in
patients with CDI. This prediction rule has been validated
through an internal split sample procedure and on an
independent cohort, and the variables are robust with
respect to clinical threshold levels identified in other
studies. These four variables can accurately assess the risk
of mortality in patients with CDI and are not themselves
defined by other parameters.
This simple prediction rule is more likely to be of
practical use in the clinical setting than previously devel-
oped more complicated prediction rules, which have yet
to become part of clinical practice. For example, the
study conducted by Bhangu et al. (2010) [11] relied on
six variables which could readily be measured, but one
variable; severity of disease, is further defined by three
more variables including sepsis, peritonitis and ≥ 10
episodes of diarrhoea in 24 hrs. The diagnosis of sepsis
is further defined by the presence of diarrhoea with at
least two other parameters that could include tachycardia
(≥ 90 bpm), pyrexia (temperature ≥ 38°C), tachypnea (≥ 20
breaths per minute) or new onset hypotension. The addition
of all these clinical parameters requires a more compli-
cated and prolonged analysis than can be undertaken in
the time constraints of a busy ward round.
The method used in this study allowed a classifier
model to use a portion of data in training to generate a
rule, which was then validated on a test data set, providing
an unbiased model with greater accuracy. This study is
unique in that it has used a decision tree model to
evaluate threshold values for significant variables identified
in multinomial logistic regression. A recent publication by
Adams and Leveson (2012) [6] states that rules generated
in this manner are generally easily understood and trans-
latable into everyday clinical practices, but could lose
accuracy if too little information is used to generate the
rule. However, we do not feel this was the case during this
study due to the comprehensive set of variables which
were analysed.the actual mortality outcome
Score for mortality Total
1 2 3
21 10 3 50
36.8 66.7 100.0 20.5
36 5 0 194
63.2 33.3 .0 79.5
57 15 3 244*
100.0 100.0 100.0 100.0
Table 3 Summary of mortality risk with increasing
prediction rule score in the derivation cohort
Score Mortality risk (%) Count (number of cases)
0 9.5 16/169
1 36.8 21/57
2 66.7 10/15
3 100 3/3
Butt et al. BMC Infectious Diseases 2013, 13:316 Page 6 of 9
http://www.biomedcentral.com/1471-2334/13/316Interpretation
The four variables; serum albumin (g/L) (P = 0.001), CRP
(mg/L) (P = 0.020), WCC ( × 103 mcL) (P = 0.025) and
respiratory rate (resps/min), (P = 0.003) were identified by
univariate and multivariate analysis as being significant
predictors of all-cause mortality in patients with CDI
(Additional file 1). These are all clinical measurements
that could be readily obtained at the time of CDI diagnosis
and are likely to be taken routinely from hospitalised
patients with symptoms suggestive of CDI, which makes
this prediction rule very accessible in a clinical setting. A
meta-analysis by Bloomfield et al., (2012) [16] and Chakra
et al., (2012) [10] also conclude that serum albumin
and WCC levels are important mortality risk factors in pa-
tients with CDI, whilst presence of fever, haemoglobin/
haematocrit level, diarrhoea severity, presence of renal disease,
diabetes, cancer, or nasogastric tube use did not appear to
be associated with mortality. This is consistent with findings
in this study which also looked at these variables in relation
to mortality and they were found not to be significant
(data not shown). A recent publication has implicated that
serum albumin, WCC and CRP are important prognostic
variables for short term mortality in patients with CDI
[17]. Other studies have found that a fall in serum albumin
level was consistent with the onset of CDI [18] as well
as being prognostic of mortality from CDI [11,17,19]
and increased WCCs have also been implicated in other
studies [11,19,20] as being prognostic of mortality in
patients with CDI.
Whilst there is no certainty that an increase/decrease in
clinical variables such as respiratory rate, WCC, CRP and
serum albumin are alone due to CDI, as these patients
are usually older, and have multiple co-morbidities, it isTable 4 Prediction rule scoring system (excluding respiratory
vs. the prediction rule derived by Bhangu et al. [11]
Prediction rule risk score
on derivation cohort (N = 244)
Prediction rule
on validation coh
Score Mortality risk Count (number of cases) Mortality risk Count
0 10.4% 13/125 20.9%
1 23.3% 20/86 37.1%
2 42.9% 12/28 54.3%
3 100% 5/5 66.7%generally seen that these markers have usually returned to
baseline levels before a later rise which occurs around the
time of C. difficile diagnosis, which could be up to 1–
2 weeks after cessation of antibiotic treatment for a previ-
ous condition. Thus, an acute rise/decline in these markers,
around the time of infection diagnosis may be generally
attributed to C. difficile infection and a combination of
all these variables would prove useful as predictors of
mortality in patients with CDI and warrants their inclu-
sion in a prediction rule, as supported by others
[11,17-20].
Other studies have suggested elevated urea as a marker
of risk of mortality, however urea levels were not evalu-
ated in this study as emphasis was placed on the % rise of
creatinine from a baseline reading as specified by the
Department of Health report [15]. Creatinine rise was not
found to be a significant predictor of mortality in this
study which might be attributed to particular emphasis
being placed on maintaining hydration in the patients on
the cohort ward, while in other clinical settings patients
at CDI diagnosis are not often initially managed by a
specialist. The role of urea will be re-evaluated in a
prospective study to ensure that it does not add statistical
strength to the prediction rule.
The (simplified) prediction rule derived in this study
was significant at classifying those patients with increased
mortality in the derivation cohort (AUC= 0.704; P < 0.001;
95% CI: 0.619-0.790) and has been made applicable to
patient cohorts obtained from non-specialist environ-
ments, by its application to a validation cohort from the
Bhangu et al. study [11]. It was shown to be consistent
in classification of patients with increased mortality risk
in the validation cohort (AUC = 0.653; P = 0.001; 95%;
CI: 0.565-0.741), with that of the prediction rule developed
in the actual study by Bhangu et al., [11] (Table 4). This
clearly shows the prediction rule was robust; even though
a key variable was missing, when tested on a new data set,
as the prediction rule remained statistically significant
even though the AUC values were reduced. It is pertinent
to note that scores of zero in both this study and that of
Bhangu et al. [11] seem to still be associated with a higher
mortality than that reflected in the CURB-65 study by Limrate) tested on derivation cohort and validation cohort
risk score
ort (N = 154)
Bhangu et al. [11] prediction
rule (N = 151)
(number of cases) Score Count (number of cases) Mortality risk
9/43 0-1 19/86 22% (Low)
23/62 2-3 31/56 55% (medium)
25/46 4-5 8/9 89% (high)
2/3
Figure 2 ROC curve for prediction rule (excluding respiratory rate) in the validation cohort (AUC = 0.653; P = 0.001; 95%; 502 CI: 0.565-0.741).
Figure 1 ROC curve for prediction rule (excluding respiratory rate) in the derivation cohort (AUC = 0.704; P < 0.001; 496 95% CI: 0.619-0.790).
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mortality. The actual mortality in the Lim et al. (2003) [7]
cohort was around 9.5%. The mortality rate for C. difficile
cohorts used for this study were 24% (derivation cohort)
and 38% (validation cohort). Therefore, clearly the base
level of mortality for the prediction rule derived in this
study will have a part to play in how discriminatory the test
can be at lower levels of mortality. In the Lim et al., (2003)
[7] study the following mortality percentages are quoted
for the CURB-65 score (in the validation cohort) 0 = 0%,
1 = 0%, 2 = 8.3%, 3 = 21.4%, 4 = 26.3, 5 = 33.3%. Analysis of
this result showed that a score of 2 or less results in a
lower risk of mortality than the mean (9.34%) and those
above 2, an increased risk. In comparison, the prediction
rule score for this study (in the validation cohort) is as
follows; 0 = 20.9%, 1 = 37.1%, 2 = 54.3%, 3 = 66.7%. The
same analysis holds true for this approach albeit for higher
overall mortality rates, with points 0 and 1 resulted in
lower than average (38%) risk of mortality and points 2
and 3 demonstrating increased risk. Thus, whilst the
CURB-65 score is undoubtedly more discriminatory at the
lower end of mortality than this proposed approach; the
characteristics of the study data, which has a much higher
mean risk of mortality, mean that the proposed rule is
better at the higher end. This may perhaps be more
helpful to someone who is first attending a patient
presenting with CDI. Finally, it should be noted that
although the zero score has an attendant mortality rate
that is significantly higher than 0%, it is also significantly
lower than the actual mean mortality in both derivation
and validation cohorts (9.5% vs. 24% in the derivation
cohort and 20.8% vs. 38% in the validation cohort). None-
theless, this prediction rule would benefit from further
prospective validation in the future.Conclusion
The prediction rule (Table 1) is based on sound statistical
analysis of this large retrospective cohort study and valid-
ation in an independent cohort.
The use of a simple prediction rule in a clinical setting
could facilitate the way in which clinicians are able to
effectively manage a patient with CDI, perhaps prompting
a different treatment regime if a high risk of mortality is
identified. The prediction rule is simple; and uses only
four variables as opposed to other studies, which use more
variables [11], and could be used by non-specialists to
consider mortality risk when assessing a patient presenting
with CDI within or around 48 hours of diagnosis. It would
also be useful in communication within teams and between
teams, for example in discussion with microbiology doctors,
as well as giving the patient and relatives information that
is evidence-based. All findings in this study strengthen the
evidence for establishment of this rule in a clinical setting.Additional file
Additional file 1: Supplementary Material.
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